

## An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis (BMS Protocol IM101240)

**Status:** Recruiting

### Eligibility Criteria

**Age:** Up to 18 years old

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

#### Inclusion Criteria:

- less than 18 years of age (unless currently or previously enrolled in an abatacept clinical trial and received abatacept) - diagnosis of Juvenile Idiopathic Arthritis (JIA) - currently receiving abatacept per treating physician's decision or received abatacept in a clinical trial

---

#### Exclusion Criteria:

- pregnant or breast feeding - history of cancer unless cancer free for at least 5 years - any serious acute or chronic medical condition other than JIA - history of frequently missing clinic appointments

### Conditions & Interventions

#### Conditions:

Arthritis & Rheumatic Diseases, Children's Health

#### Keywords:

Abatacept, Juvenile Idiopathic Arthritis

### More Information

**Description:** The objective of this study is to create an international registry with long-term follow-up to characterize and evaluate the safety of abatacept in juvenile idiopathic arthritis (JIA). The primary objective of the JIA registry is to describe the long-term safety of abatacept treatment for JIA by quantifying the incidence rates of serious infections, autoimmune disorders, and malignancies.

**Contact(s):** Bryce Binstadt - binstadt@umn.edu

**Principal Investigator:** Colleen Correll

#### IRB

**Number:** 1403M48721

**System ID:** 16752

---

Thank you for choosing StudyFinder. Please visit <http://studyfinderstaging.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.